# US 2024/0417697 A1 · Methods and compositions for bat ipsc preparation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0417697 A1
- Document ID: US20240417697A1
- Status: Published application
- Kind: A1
- Application number: 18/691,516
- Filed: 2022-09-26
- Published: 2024-12-19
- Earliest claimed: 2021-09-27
- Assignees: Icahn School of Medicine at Mount Sinai
- Applicants: Icahn School of Medicine at Mount Sinai
- Inventors: Thomas P. Zwaka; Marion Dejosez Zwaka; Adolfo Garcia- Sastre
- Web page: https://patentgrep.com/patent/US20240417697A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2502/1323: Adult fibroblasts
- C12N 2506/1307: from adult fibroblasts
- C12N 2513/00: 3D culture
- C12N 2533/54: Collagen; Gelatin
- C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/10051: Methods of production or purification of viral material
- C12N 2740/13021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20051: Methods of production or purification of viral material
- C12N 2770/36121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are compositions and methods of making and using bat IPSCs (BipS). Also disclosed herein are methods and compositions of virus nucleic acids residing in bat IPSCs. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

## Claims

### Claim 1

An induced pluripotent bat stem cell (bat IPSC), wherein the cell is in a pluripotent state.

### Claim 2 (depends on 1)

The bat IPSC of claim 1, wherein the cell is in a pluripotent state characterized by the expression of one or more factors selected from the group of Klf4, Klf17, Essrb, Tfcp2l1, Tfe3, Dppa, Oct4, Sox2, Nanog, and Dusp6.

### Claim 3 (depends on 1, 2)

The bat IPSC of claim 1 or 2, wherein the cell is in a naïve pluripotent state.

### Claim 4 (depends on 1, 2, 3)

The bat IPSC of any one of claims 1-3, wherein the cell further is characterized by the expression of one or more factors selected from the group of Otx2 or Zic2.

### Claim 5 (depends on 1, 2, 3, 4)

The bat IPSC of any one of claims 1-4, wherein the cell is derived from a bat fibroblast.

### Claim 6 (depends on 5)

The bat IPSC of claim 5, wherein the cell is derived from a bat embryonic fibroblast or a bat fibroblast from an adult bat.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The bat IPSC of any one of claims 1-6, wherein the cell is derived from a Rhinolophus bat or a Myotis bat.

### Claim 8 (depends on 7)

The bat IPSC of claim 7, wherein the cell is derived from a Rhinolophus ferrumequinum bat or a Myotis myotis bat.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The bat IPSC of any one of claims 1-8, wherein the cell is capable of differentiating into embryonic bodies.

### Claim 10 (depends on 9)

The bat IPSC of claim 9, wherein the embryonic bodies are capable of differentiating into three-dimensional structures comprising three germ layer markers.

### Claim 11

A method of producing induced pluripotent bat stem cells (bat IPSCs), the method comprising:
(i) reprogramming isolated bat cells with Oct4, Sox2, cMyc, and Klf4 factors;
(ii) culturing the reprogrammed cells on feeder cells in a medium comprising FGF, Leukemia inhibitory factor (Lif), SCF, and Forskolin until colonies appear; and
(iii) splitting cells using a low concentration EDTA buffer;
thereby producing IPSCs from bats.

### Claim 12 (depends on 11)

The IPSCs produced by the method of claim 11.

### Claim 13 (depends on 11, 12)

The method of claim 11 or claim 12, wherein the isolated bat cell is a bat fibroblast.

### Claim 14 (depends on 13)

The method of claim 13, wherein the isolated bat cell is a bat embryonic fibroblast or an bat adult fibroblast.

### Claim 15 (depends on 11, 12, 13, 14)

The method of any one of claims 11-14, wherein the isolated bat cell is derived from a Rhinolophus bat.

### Claim 16 (depends on 15)

The method of claim 15, wherein the isolated bat cell is derived from a Rhinolophus ferrumequinum bat.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The method of any one of claims 11-16, wherein the Lif is at a concentration of 10∝U/ml.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 11-17, wherein the FGF is at a concentration of 100 ng/ml.

### Claim 19 (depends on 11)

The method of any one of claims 11,-18 wherein the SCF is at a concentration of 100 ng/ml.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 11-19, wherein the Forskolin is at a concentration of 20 nM.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 11-20, wherein the feeder cell is a mouse CF1 mouse embryonic fibroblasts (MEF).

### Claim 22 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 11-21, the method further comprising passaging the bat IPSCs every 5 days onto feeder cells.

### Claim 23 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 11-22, wherein the bat IPSC is further differentiated into embryonic bodies.

### Claim 24 (depends on 23)

The method of claim 23 wherein the embryonic bodies are further differentiated into three-dimensional structures comprising three germ layer markers.

### Claim 25

A method of producing induced pluripotent bat stem cells (bat IPSCs), the method comprising:
(i) reprogramming isolated bat cells with Oct4, Sox2, cMyc, and Klf4 factors;
(ii) culturing the reprogrammed cells in feeder free medium comprising FGF, Leukemia inhibitory factor (Lif), SCF, and Forskolin until colonies appear; and
(iii) splitting cells using a low concentration EDTA buffer
thereby producing IPSCs from bats.

### Claim 26

A composition for reprogramming a bat cell to produce pluripotent stem cells comprising a medium comprising FGF, Leukemia inhibitory factor (Lif), SCF, and Forskolin.

### Claim 27 (depends on 18)

The composition of claim 18, wherein the Lif is at a concentration of 10{circumflex over ( )}4 U/ml.

### Claim 28 (depends on 18)

The composition of claim 18, wherein the FGF is at a concentration of 100 ng/ml.

### Claim 29 (depends on 18)

The composition of claim 18, wherein the SCF is at a concentration of 100 ng/ml.

### Claim 30 (depends on 18)

The composition of claim 18, wherein the Forskolin is at a concentration of 20 nM.

### Claim 31

A method of obtaining viral sequences from bat IPSCs, the method comprising
obtaining bat IPSCs;
identifying viral sequences residing in the bat iPSC genome or intracellular virus genome; and
assembling the viral sequences;
thereby obtaining viral sequences from the bat iPSCs.

### Claim 32 (depends on 31)

The method of claim 31, wherein the identifying comprises sequencing the bat genome or the genome of viral particles residing in the bat IPSCs, or of viral particles shed by the bat IPSCs.

### Claim 33 (depends on 31, 32)

The method of claim 31 or claim 32, wherein the identifying comprises sequencing the RNA of the bat genome or the genome of viral particles residing in the bat IPSCs, or of viral particles shed by the bat IPSCs.

### Claim 34 (depends on 31)

The method of claim 31, wherein the identifying the proteins and peptides produced by the viral genome by proteomics e.g., LC-MS.

### Claim 35 (depends on 31)

The method of claim 31, further comprising translating the sequence into a protein sequence and determining whether the translated sequence has a significant homology to a known protein sequence in a viral protein database.

### Claim 36 (depends on 35)

The method of claim 35, wherein the sequence is selected from SEQ ID NO: 1-349.

### Claim 37 (depends on 31)

The method of claim 31, wherein the virus is selected from the group of a SARS-CoV-2 virus, endogenous retrovirus (RfRV), and sindbis virus.

### Claim 38 (depends on 31)

The method of claim 31, wherein the virus is a coronavirus.

### Claim 39 (depends on 35)

The method of claim 35, wherein the sequence is encoding a gag protein, a pol protein, or an env Protein.

### Claim 40

A method of obtaining viral sequences from virus particles shed by bat IPSCs or cells derived from bat IPSCs, the method comprising
obtaining bat IPSCs or cells derived from bat IPSCs;
culturing the bat IPSCs or cells derived from bat IPSCs under conditions that allows shedding of virus particles into the culture media;
collecting the culture media;
identifying viral sequences residing in the culture media; and
assembling the viral sequences,
thereby obtaining viral sequences from virus particles shed by bat iPSCs or cells derived from bat IPSCs.

### Claim 41 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

Use of any one of the viral sequences of claims 31-40 for the development of a vaccine.

### Claim 42

A recombinant nucleic acid molecule, comprising
a promoter, and
a nucleic acid selected from SEQ ID NO: 1-349 encoding for a viral protein or fragment thereof.

### Claim 43 (depends on 42)

A recombinant, replication deficient adenovirus, comprising the nucleic acid of claim 42.

### Claim 44 (depends on 42)

A mRNA comprising the nucleic acid of claim 42.

### Claim 45

An expression vector comprising
a promoter and
a nucleic acid selected from SEQ ID NO: 1-349 encoding for a viral protein or fragment thereof.

### Claim 46

An isolated protein or peptide comprising an amino acid sequence encoded in a nucleic acid set forth in SEQ ID NO: 1-349, wherein the peptide is no more than 100 amino acids in length, and an optional pharmaceutically acceptable carrier.

### Claim 47 (depends on 46)

The isolated protein or peptide of claim 46, wherein the protein or peptide is no more than 30 amino acids in length or 20 amino acids in length.

### Claim 48 (depends on 46, 47)

The isolated protein or peptide of claims 46 or 47, where the protein or peptide is synthetic.

### Claim 49 (depends on 43, 44, 46, 47, 48)

A pharmaceutical composition comprising the adenovirus of claim 43, the mRNA of claim 44, or the protein or peptide of any one of claims 46-48 and a pharmaceutically acceptable carrier or excipient.

### Claim 50 (depends on 46, 47, 48)

A pharmaceutical composition comprising a plurality of (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) proteins or peptides of any one of claims 46-48 and a pharmaceutically acceptable carrier or excipient.

### Claim 51 (depends on 44, 46, 47, 48)

A pharmaceutical composition comprising a nucleic acid encoding the mRNA of claim 44 or the protein or peptide of any one of claims 46-48 and a pharmaceutically acceptable carrier or excipient.

### Claim 52 (depends on 44, 46, 47, 48)

A pharmaceutical composition comprising one or more nucleic acids encoding a plurality of (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) mRNAs of claim 44 or proteins or peptides of any one of claims 46-48, and a pharmaceutically acceptable carrier or excipient.

### Claim 53 (depends on 49, 50, 51, 52)

The pharmaceutical composition of any one of claims 49-52, further comprising a liposome, wherein the protein or peptide or the nucleic acid encoding the protein or peptide is disposed within the liposome.

### Claim 54 (depends on 49, 50, 51, 52)

The pharmaceutical composition of any one of claims 49-52, further comprising a lipid nanoparticle, wherein the protein or peptide or the nucleic acid encoding the protein or peptide is disposed within the lipid nanoparticle.

### Claim 55 (depends on 49, 50, 51, 52, 53, 54)

The pharmaceutical composition of any one of claims 49-54, further comprising an immunogenicity enhancing adjuvant.

### Claim 56 (depends on 49, 50, 51, 52, 53, 54, 55)

The pharmaceutical composition of any one of claims 49-55, wherein the protein or peptide or nucleic acid encoding the protein or peptide is synthetic.

### Claim 57 (depends on 49, 50, 51, 52, 53, 54, 55, 56)

A vaccine that stimulates a T cell mediated immune response when administered to a subject, the vaccine comprising the pharmaceutical composition of any one of claims 49-56.

### Claim 58 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57)

A vaccine comprising the pharmaceutical composition of any one of claims 49-57.

### Claim 59 (depends on 57, 58)

The vaccine of claims 57 or 58, wherein the vaccine is a priming vaccine and/or a booster vaccine.

### Claim 60

A recombinant cell comprising a nucleic acid or a portion of a nucleic acid set forth in SEQ ID NO: 1-349.

### Claim 61

A recombinant cell comprising a protein or a portion of a protein encoded by a nucleic acid set forth in SEQ ID NO: 1-349.

### Claim 62

A composition comprising an inhibitor of a protein encoded by a nucleic acid selected from SEQ ID NO: 1-349.
